BioMarin Pharmaceutical (NASDAQ: BMRN) Hosts Q2 2026 Financial Results Conference Call and Webcast Thursday August 6 at 4:30 PM ET Alongside Amylyx Pharmaceuticals (NASDAQ: AMLX) and Tarsus Pharmaceuticals (NASDAQ: TARS) Reporting Thursday Morning; BioMarin Focus on Voxzogo (Vosoritide, C-Type Natriuretic Peptide Analog for Achondroplasia) Commercial Trajectory, ROCTAVIAN (Valoctocogene Roxaparvovec Hemophilia A Gene Therapy), Palynziq for Phenylketonuria, and the Broader Rare-Disease Enzyme Replacement Franchise That Includes VIMIZIM, Naglazyme, and Aldurazyme
BioMarin Pharmaceutical (NASDAQ: BMRN) hosts its Q2 2026 financial results conference call and webcast Thursday August 6, 2026 at 4:30 PM ET. Analyst focus areas: Voxzogo (vosoritide) commercial trajectory in achondroplasia (Voxzogo is a C-type natriuretic peptide analog administered by daily subcutaneous injection, making it a substantive peptide franchise for the site's coverage); ROCTAVIAN (valoctocogene roxaparvovec) hemophilia A AAV gene therapy commercial ramp and payer coverage; Palynziq (pegvaliase-pqpz) for phenylketonuria (PKU) revenue trajectory; and the broader rare-disease enzyme replacement franchise including VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), and Aldurazyme (laronidase). BioMarin has been transitioning its commercial focus from the mature enzyme replacement franchise toward newer growth drivers (Voxzogo and ROCTAVIAN) with analyst attention on the balance of growth-portfolio contribution versus legacy-franchise stability. Amylyx Pharmaceuticals (NASDAQ: AMLX) also reports Q2 2026 results Thursday August 6 at 8:00 AM ET, with focus on the amyotrophic lateral sclerosis (ALS) pipeline following the March 2024 US withdrawal of Relyvrio and pipeline reprioritization to progressive supranuclear palsy (PSP) and other rare neurodegenerative indications. Tarsus Pharmaceuticals (NASDAQ: TARS) reports at 8:00 AM ET.